Variable | Footwear intervention group (n = 47) | Control group (n = 47) |
---|---|---|
Sex, male, n (%) | 40 (85%) | 43 (91%) |
Age, years | 62.6 (17.0) | 62.4 (13.7) |
BMI, kg/m2 | 30.2 (6.4) | 32.0 (7.0) |
Ethnicity, n (%) | ||
NZ European | 28 (62%) | 26 (57%) |
Pacific | 6 (13%) | 11 (23%) |
Asian | 7 (16%) | 5 (11%) |
Māori | 4 (9%) | 4 (9%) |
Gout history, mean (SD) | ||
Disease duration (years) | 12.2 (11.2) | 13.6 (12.3) |
Flares prior 3 months | 0.7 (0.9) | 0.4 (0.7) |
Foot tophus, n (%) | 9 (19%) | 17 (36%) |
Any tophus, n (%) | 13 (28%) | 24 (51%) |
Serum urate, mmol/L | 0.39 (0.13) | 0.38 (0.11) |
Medications, n (%) | ||
Urate-lowering therapy | 33 (72%) | 30 (64%) |
Colchicine | 15 (33%) | 17 (36%) |
Prednisone | 9 (20%) | 10 (21%) |
NSAID | 12 (27%) | 13 (29%) |
Diuretic | 8 (18%) | 5 (11%) |
Medical History, n (%) | ||
Hypertension | 22 (48%) | 22 (54%) |
Cardiovascular disease | 13 (28%) | 11 (24%) |
Type 2 diabetes | 7 (15%) | 3 (7%) |
Peripheral vascular disease | 4 (9%) | 3 (7%) |
Peripheral neuropathy | 3 (7%) | 5 (11%) |